产品说明书

DPPC

Print
Chemical Structure| 63-89-8 同义名 : 二棕榈酰磷脂酰胆碱 ;129Y83;1,2-Dipalmitoyl-sn-glycero-3-phosphorylcholine;1,2-Dipalmitoyl-sn-glycero-3-PC;L-Dipalmitoyl Lecithin;L-DPPC
CAS号 : 63-89-8
货号 : A542590
分子式 : C40H80NO8P
纯度 : 95%
分子量 : 734.039
MDL号 : MFCD00036903
存储条件：

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

无水乙醇: 25 mg/mL(34.06 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇
动物实验配方：
生物活性
描述 Colfosceril palmitate (dipalmitoylphosphatidylcholine) is the primary surface-active agent of natural lung surfactant and the major constituent of exogenous surface replacement preparations[3]. The use of beractant and colfosceril palmitate in premature infants has clearly decreased morbidity and mortality associated with RDS(respiratory distress syndrome)[4]. Phosphatidylcholine and colfosceril palmitate in serum as well as xanthurenic acid, naphthalenesulfonic acid, and pimelylcarnitine in urine might be metabolic biomarkers due to their promising diagnostic potential at the early stage of the infection[5]. Rescue therapy with colfosceril palmitate in infants with NRDS (neonatal respiratory distress syndrome) and birthweights over 1250g can result in substantial reductions in hospital resource utilisation and charges in addition to the clinical benefits associated with its use[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.36mL

0.27mL

0.14mL

6.81mL

1.36mL

0.68mL

13.62mL

2.72mL

1.36mL
参考文献

[1]Dechant KL, Faulds D. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome. Drugs. 1991 Nov;42(5):877-94.

[2]Abrahamson EL, Viswanath M, et al. Unilateral pulmonary interstitial emphysema and treatment with colfosceril palmitate. Lancet. 1993 Jun 19;341(8860):1603.

[3]Dechant KL, Faulds D. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome. Drugs. 1991 Nov;42(5):877-94

[4]Ishisaka DY. Exogenous surfactant use in neonates. Ann Pharmacother. 1996 Apr;30(4):389-98

[5]Hu Y, Chen J, Xu Y, Zhou H, Huang P, Ma Y, Gao M, Cheng S, Zhou H, Lv Z. Alterations of Gut Microbiome and Metabolite Profiling in Mice Infected by Schistosoma japonicum. Front Immunol. 2020 Oct 8;11:569727

[6]Backhouse ME, Mauskopf JA, Jones D, Wold DE, Schumacher R, Cotton R, Long WA. Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250g or more with respiratory distress syndrome: results from a randomised trial. Pharmacoeconomics. 1994 Oct;6(4):358-69